Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease

被引：1
作者：
Samantha Budd Haeberlein
P.S. Aisen
F. Barkhof
S. Chalkias
T. Chen
S. Cohen
G. Dent
O. Hansson
K. Harrison
C. von Hehn
T. Iwatsubo
C. Mallinckrodt
C.J. Mummery
K.K. Muralidharan
I. Nestorov
L. Nisenbaum
R. Rajagovindan
L. Skordos
Y. Tian
C.H. van Dyck
B. Vellas
S. Wu
Y. Zhu
A. Sandrock
机构：
[1] Biogen,Alzheimer’s Therapeutic Research Institute
[2] University of Southern California,Clinical Memory Research Unit, Department of Clinical Sciences
[3] Department of Radiology and Nuclear Medicine,Memory Clinic
[4] Amsterdam UMC,Department of Neuropathology, Graduate School of Medicine
[5] UCL Queen Square Institute of Neurology & Centre for Medical Image Computing,Dementia Research Centre, Queen Square Institute of Neurology
[6] Toronto Memory Program,Alzheimer’s Disease Research Unit
[7] Lund University,Toulouse Gerontopole University Hospital
[8] Skåne University Hospital,undefined
[9] The University of Tokyo,undefined
[10] University College London,undefined
[11] Yale School of Medicine,undefined
[12] Universite Paul Sabatier,undefined
[13] INSERM U 1295,undefined
来源：
The Journal of Prevention of Alzheimer's Disease | 2022年 / 9卷 / 2期
关键词：
Aducanumab; Alzheimer’s disease; amyloid beta;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：197 / 210
页数：13
相关论文
共 90 条
[1]  
Jack CR(2018)NIA-AA research framework: toward a biological definition of Alzheimer’s disease Alzheimers Dement 14 535-562
[2]  
Bennett DA(1992)Alzheimer’s disease: the amyloid cascade hypothesis Science 256 184-185
[3]  
Blennow K(2016)The amyloid hypothesis of Alzheimer’s disease at 25 years EMBO Mol Med 8 595-608
[4]  
Hardy JA(2015)Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials Neurology 85 692-700
[5]  
Higgins GA(2018)Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloidbeta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE) Alzheimers Res. Ther. 10 96-120
[6]  
Selkoe DJ(2016)Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients Alzheimers Dement. 12 110-56
[7]  
Hardy J(2016)The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease Nature 537 50-1704
[8]  
Liu E(2021)A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody Alzheimers Res. Ther. 13 80-21
[9]  
Schmidt ME(2021)Donanemab in early Alzheimer’s disease N Engl J Med. 384 1691-279
[10]  
Margolin R(2022)Amyloid-related imaging abnormalities in 2 Phase 3 studies evaluating aducanumab in patients with early Alzheimer disease JAMA Neurol. 79 13-269
123456789